ArticlePediatrics2015
First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.
Article in Pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review.Journal of global health · 2019Pooled it
- Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, CanadaEmerging infectious diseases · 2020Trial
- Evaluation of Educational Interventions to Enhance Adolescent Specific Vaccination Coverage.The Journal of school health · 2019Trial
- Emergence of short-lived meningococci causing focal epidemics can be associated with gene transfer from carriage-associatedbioRxiv : the preprint server for biology · 2026Article
- Low Incidence of Relapses After Vaccination in Anti-Aquaporin-4 Antibody-Positive NMOSD.Annals of clinical and translational neurology · 2026Observational
- Review
- The Influence of Introducing Free Vaccination againstVaccines · 2023Article
- Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review.Infectious diseases and therapy · 2023Review
- Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review.Human vaccines & immunotherapeutics · 2023Review
- Understanding Vaccine Safety and the Roles of the FDA and the CDC.The New England journal of medicine · 2022Review
- Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.Vaccine · 2022Article
- Containing the spread of mumps on college campuses.Royal Society open science · 2022Article
- Meningococcal Disease Outbreaks: A Moving Target and a Case for Routine Preventative Vaccination.Infectious diseases and therapy · 2021Review
- Herd Protection against Meningococcal Disease through Vaccination.Microorganisms · 2020Review
- US College Students Are at Increased Risk for Serogroup B Meningococcal Disease.Journal of the Pediatric Infectious Diseases Society · 2020Article
- Insights on Population Structure and Within-Host Genetic Changes among Meningococcal Carriage Isolates from U.S. Universities.mSphere · 2020Article
- Effect of complement Factor H on antibody repertoire and protection elicited by meningococcal capsular group B vaccines containing Factor H binding protein.Human vaccines & immunotherapeutics · 2020Article
- Article
- Outbreak strain characterisation and pharyngeal carriage detection following a protracted group B meningococcal outbreak in adolescents in South-West England.Scientific reports · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundIn 2013-2014, an outbreak of serogroup B meningococcal disease occurred among persons linked to a New Jersey university (University A). In the absence of a licensed serogroup B meningococcal (MenB) vaccine in the United States, the Food and Drug Administration authorized use of an investigational MenB vaccine to control the outbreak. An investigation of the outbreak and response was undertaken to determine the population at risk and assess vaccination coverage.
methodsThe epidemiologic investigation relied on compilation and review of case and population data, laboratory typing of meningococcal isolates, and unstructured interviews with university staff. Vaccination coverage data were collected during the vaccination campaign held under an expanded-access Investigational New Drug protocol.
resultsBetween March 25, 2013, and March 10, 2014, 9 cases of serogroup B meningococcal disease occurred in persons linked to University A. Laboratory typing results were identical for all 8 isolates available. Through May 14, 2014, 89.1% coverage with the 2-dose vaccination series was achieved in the target population. From the initiation of MenB vaccination through February 1, 2015, no additional cases of serogroup B meningococcal disease occurred in University A students. However, the ninth case occurred in March 2014 in an unvaccinated close contact of University A students.
conclusionsNo serogroup B meningococcal disease cases occurred in persons who received 1 or more doses of 4CMenB vaccine, suggesting 4CMenB may have protected vaccinated individuals from disease. However, the ninth case demonstrates that carriage of serogroup B Neisseria meningitidis among vaccinated persons was not eliminated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.